<DOC>
	<DOCNO>NCT02951026</DOCNO>
	<brief_summary>This long-term extension study design monitor long-term safety , tolerability , efficacy treatment SM04690 placebo previously inject target knee joint subject moderately severely symptomatic osteoarthritis ( OA ) Samumed-sponsored SM04690-OA phase 2 phase 3 study . No additional SM04690 placebo therapy administer study .</brief_summary>
	<brief_title>An Observational Study Evaluating Safety , Tolerability , Efficacy Treatment SM04690 Placebo Previously Injected Target Knee Joint Subjects With Moderately Severely Symptomatic Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Completion schedule endofstudy visit Samumedsponsored SM04690OA phase 2 phase 3 study Full understanding requirement study willingness comply study visit assessment Subjects must read understood informed consent form , must sign prior studyrelated procedure perform Unable undergo radiograph procedure detail within protocol Partial complete joint replacement target knee Subjects immediate family member ( spouse , parent , child , sibling ; biological legally adopt ) personnel directly affiliate study investigative site , directly affiliate study investigative site Subjects employ Samumed , LLC , affiliate development partner ( , employee , temporary contract worker , designee ) responsible conduct study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>knee</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>intra-articular injection</keyword>
	<keyword>SM04690</keyword>
</DOC>